Advertisement

Development of Vaccine Therapy for Pancreas Cancer

  • Dung Le
  • Elizabeth M. Jaffee
  • Dan Laheru
Part of the M. D. Anderson Solid Tumor Oncology Series book series (MDA)

Despite recent advances in drug therapies for cancer, pancreatic cancer remains one of the most difficult cancers to treat at any stage. As with many solid tumors, the only opportunity for cure is complete resection. Unfortunately, only 20–30% of patients are eligible for resection, and even for resected patients the 5-year survival is 15–20% (1–3). For a majority of the 33,000 patients diagnosed each year, this disease is fatal and prolonged survival is rare (4, 5). Although other cancers are increasingly being viewed as chronic in nature, this is not the case for pancreatic cancer. The median survival for patients with metastatic disease is 3–6 months and current treatments provide marginal survival benefits.

The mainstay of therapy for pancreatic cancer has been surgery, radiation, and chemotherapy. Newer studies are integrating targeted agents with some incremental benefits ( 6 ). Conventional therapies have not been effective in the treatment of pancreatic cancer and innovative approaches are necessary to make an impact in this disease.

Keywords

Pancreatic Cancer Dendritic Cell Antitumor Immunity Advanced Pancreatic Cancer Donor Lymphocyte Infusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004, 363 (9414): 1049–1057.PubMedGoogle Scholar
  2. 2.
    Sohn TA, Yeo CJ, Cameron JL, 2000, Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 4(6):567–579.PubMedGoogle Scholar
  3. 3.
    Yeo CJ, Pluth-Yeo T, Hruban R, et al. Cancer of the pancreas. In: Devita VT (ed.) Principles and practice of oncology, 7th ed. Philadelphia, Lippincott, 2005, 945.Google Scholar
  4. 4.
    American Cancer Society. Cancer facts and figures2006. Atlanta, American Cancer Society, 2006.Google Scholar
  5. 5.
    DeVita VT, Hellman S, Rosenberg SA. 2005, Cancer: principles & practice of oncology, Lippincott Williams & Wilkins, Philadelphia, 7th ed.Google Scholar
  6. 6. Moore MJ, Hamm J, Kotecha J, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A Phase III Trial of the NCI of Canada Clinical Trials Group. Am Soc Clin Oncol. 2005, Abstract 77.Google Scholar
  7. 7. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. with a report of ten original cases. 1893. Clin Orthop Relat Res 1991, (262):3-11.Google Scholar
  8. 8.
    Lawrence HS (ed). 1959, Discussion of cellular and humoral aspects of the hypersensitive states. Hoeber-Harper, New York.Google Scholar
  9. 9.
    Burnet FM. 1970, The concept of immunological surveillance. Prog Exp Tumor Res 13:1–27.PubMedGoogle Scholar
  10. 10.
    Gaidano G, Dalla-Favera R. 1992, Biologic aspects of human immunodeficiency virus-related lymphoma. Curr Opin Oncol 4(5):900–906.PubMedGoogle Scholar
  11. 11.
    Coiffier B, Lepage E, Briere J, 2002, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (4):235–242.PubMedGoogle Scholar
  12. 12.
    Held G, Poschel V, Pfreundschuh M. 2006, Rituximab for the treatment of diffuse large B-cell lymphomas. Expert Rev Anticancer Ther 6(8):1175–1186.PubMedGoogle Scholar
  13. 13.
    Pfreundschuh M, Trumper L, Osterborg A, 2006, CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group. Lancet Oncol 7(5):379–391.PubMedGoogle Scholar
  14. 14.
    Atkins MB, Lotze MT, Dutcher JP, 1999, High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17(7):2105–2116.PubMedGoogle Scholar
  15. 15.
    Chang DH, Liu N, Klimek V, 2006, Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: Therapeutic implications. Blood 108(2):618–621.PubMedGoogle Scholar
  16. 16.
    Teo SK. 2005, Properties of thalidomide and its analogues: Implications for anticancer ther-apy. AAPS J 7(1):E14–19.PubMedGoogle Scholar
  17. 17.
    Biggs JC, Szer J, Crilley P, 1992, Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 80(5):1352–1357.PubMedGoogle Scholar
  18. 18.
    Cummins M, Cwynarski K, Marktel S, 2005, Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the clinical trials committee of the british society of blood & marrow transplantation (BSBMT). Bone Marrow Transplant 36(12):1065–1069.PubMedGoogle Scholar
  19. 19.
    Weisser M, Tischer J, Schnittger S, 2006, A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 91(5):663–666.PubMedGoogle Scholar
  20. 20.
    Wu CJ, Biernacki M, Kutok JL, 2005, Graft-versus-leukemia target antigens in chronic myel-ogenous leukemia are expressed on myeloid progenitor cells. Clin Cancer Res 11 (12):4504–4511.PubMedGoogle Scholar
  21. 21.
    Dudley ME, Wunderlich JR, Yang JC, 2005, Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23(10):2346–2357.PubMedGoogle Scholar
  22. 22.
    Abeloff MD (ed). 2004 Clinical oncology, 3 Elsevier Churchill Livingstone, Philadelphia, rd ed..Google Scholar
  23. 23.
    Hruban RH, Offerhaus GJ, Kern SE, 1998, Tumor-suppressor genes in pancreatic cancer. J Hepatobiliary Pancreat Surg 5(4):383–391.PubMedGoogle Scholar
  24. 24.
    Hruban RH, Mansfeld AD, van Offerhaus GJ, 1993, K-Ras oncogene activation in adenocar-cinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143(2):545–554.PubMedGoogle Scholar
  25. 25.
    Laheru D, Jaffee EM. 2005, I mmunotherapy for pancreatic cancer—science driving clinical progress. Nat Rev Cancer 5(6):459–467.PubMedGoogle Scholar
  26. 26.
    Laheru D, Biedrzycki B, Jaffee EM. 2001, I mmunologic approaches to the management of pancreatic cancer. Cancer J 7(4):324–337.PubMedGoogle Scholar
  27. 27.
    Hruban RH, Goggins M, Parsons J, 2000, Progression model for pancreatic cancer. Clin Cancer Res 6(8):2969–2972.PubMedGoogle Scholar
  28. 28.
    Sohn TA, Yeo CJ. 2000, The molecular genetics of pancreatic ductal carcinoma: A review. Surg Oncol 9(3):95–101.PubMedGoogle Scholar
  29. 29.
    Wilentz RE, Su GH, Dai JL, 2000, Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol 156 (1):37–43.PubMedGoogle Scholar
  30. 30.
    Bos JL. 1989, Ras oncogenes in human cancer: a review. Cancer Res 49(17):4682–4689.PubMedGoogle Scholar
  31. 31.
    Zehn D, Bevan MJ. 2006, T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. I mmunity 25(2):261–270.Google Scholar
  32. 32.
    Martignoni ME, Kunze P, Hildebrandt W, 2005, Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res 11(16):5802–5808.PubMedGoogle Scholar
  33. 33.
    Shibata M, Nezu T, Kanou H, 2002, Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J Clin Gastroenterol 34(4):416–420.PubMedGoogle Scholar
  34. 34.
    Bernstorff W, von Voss M, Freichel S, 2001, Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7(3 Suppl):925s–932s.Google Scholar
  35. 35.
    Schmielau J, Nalesnik MA, Finn OJ. 2001, Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. Clin Cancer Res 7(3 Suppl): 933–939.Google Scholar
  36. 36.
    Wolf AM, Wolf D, Steurer M, 2003, Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9(2):606–612.PubMedGoogle Scholar
  37. 37.
    Curiel TJ, Coukos G, Zou L, 2004, Specific recruitment of regulatory T cells in ovarian carci-noma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942–949.PubMedGoogle Scholar
  38. 38.
    Liyanage UK, Moore TT, Joo HG, 2002, Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169(5):2756–2761.PubMedGoogle Scholar
  39. 39.
    Berendt MJ, North RJ. 1980, T-cell-mediated suppression of anti-tumor immunity. an expla-nation for progressive growth of an immunogenic tumor. J Exp Med 151 (1): 69–80.PubMedGoogle Scholar
  40. 40.
    Sakaguchi S, Sakaguchi N, Shimizu J, 2001, Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. I mmunol Rev 182:18–32.Google Scholar
  41. 41.
    Hori S, Nomura T, Sakaguchi S. 2003, Control of regulatory T cell development by the tran-scription factor Foxp3. Science 299(5609):1057–1061.PubMedGoogle Scholar
  42. 42.
    Fontenot JD, Gavin MA, Rudensky AY. 2003, Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4(4):330–336.PubMedGoogle Scholar
  43. 43.
    Alpan RS, Zhang M, Pardee AB. 1996, Cell cycle-dependent expression of TAP1, TAP2, and HLA-B27 messenger RNAs in a human breast cancer cell line. Cancer Res 56 (19):4358–4361.PubMedGoogle Scholar
  44. 44.
    Huang AY, Bruce AT, Pardoll DM, 1996, In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 4(4):349–355.PubMedGoogle Scholar
  45. 45.
    Seliger B, Hohne A, Knuth A, 1996, Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin Cancer Res 2(8):1427–1433.PubMedGoogle Scholar
  46. 46.
    Restifo NP, Kawakami Y, Marincola F, 1993, Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompati-bility complex class I. J Immunother 14(3):182–190.Google Scholar
  47. 47.
    Wang Z, Cao Y, Albino AP, 1993, Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J Clin Invest 91(2):684–692.PubMedGoogle Scholar
  48. 48.
    Ferrone S, Marincola FM. 1995, Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. I mmunol Today 16 (10):487–494.Google Scholar
  49. 49.
    Yee C, Thompson JA, Byrd D, 2002, Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migra-tion, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99 (25):16168–16173.PubMedGoogle Scholar
  50. 50.
    Uyttenhove C, Maryanski J, Boon T. 1983, Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 157 (3):1040–1052.PubMedGoogle Scholar
  51. 51.
    Bromberg JF, Wrzeszczynska MH, Devgan G, 1999, Stat3 as an oncogene. Cell 98(3):295–303.PubMedGoogle Scholar
  52. 52.
    Kortylewski M, Kujawski M, Wang T, 2005, Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11(12):1314–1321.PubMedGoogle Scholar
  53. 53.
    Wang T, Niu G, Kortylewski M, 2004, Regulation of the innate and adaptive immune responses by stat-3 signaling in tumor cells. Nat Med 10(1):48–54.PubMedGoogle Scholar
  54. 54.
    Cheng F, Wang HW, Cuenca A, 2003, A critical role for Stat3 signaling in immune tolerance. Immunity 19(3):425–436.PubMedGoogle Scholar
  55. 55.
    Sharma S, Stolina M, Yang SC, 2003, Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 9(3):961–968.PubMedGoogle Scholar
  56. 56.
    Drake CG, Jaffee E, Pardoll DM. 2006, Mechanisms of immune evasion by tumors. Adv Immunol 90:51–81.PubMedGoogle Scholar
  57. 57.
    Apolloni E, Bronte V, Mazzoni A, 2000, Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J Immunol 165(12):6723–6730.PubMedGoogle Scholar
  58. 59.
    Kusmartsev S, Gabrilovich DI. 2006, Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 55(3):237–245.PubMedGoogle Scholar
  59. 60.
    Kusmartsev S, Nefedova Y, Yoder D, 2004, Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 172(2):989–999.PubMedGoogle Scholar
  60. 61.
    Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. 2005, Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11 (3): 312–319.PubMedGoogle Scholar
  61. 62.
    Munn DH, Sharma MD, Hou D, 2004, Expression of indoleamine 2,3-dioxygenase by plas-macytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114 (2): 280–290.PubMedGoogle Scholar
  62. 63.
    Uyttenhove C, Pilotte L, Theate I, 2003, Evidence for a tumoral immune resistance mecha-nism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9 (10):1269–1274.PubMedGoogle Scholar
  63. 64.
    Apostolopoulos V, McKenzie IF. 1994, Cellular mucins: targets for immunotherapy. Crit Rev Immunol 14(3-4):293–309.PubMedGoogle Scholar
  64. 65.
    Hammarstrom S. 1999, The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9(2):67–81.PubMedGoogle Scholar
  65. 66.
    Harris JC, Gilliam AD, McKenzie AJ, 2004, The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas. Cancer Res 64(16):5624–5631.PubMedGoogle Scholar
  66. 67.
    Nakatsura T, Senju S, Ito M, 2002, Cellular and humoral immune responses to a human pan-creatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 32(3):826–836.PubMedGoogle Scholar
  67. 68.
    Rosenberg SA. 2001, Progress in human tumour immunology and immunotherapy. Nature 411(6835):380–384.PubMedGoogle Scholar
  68. 69.
    Boon T, Cerottini JC, den Eynde B, Van 1994, Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337–365.PubMedGoogle Scholar
  69. 70.
    Argani P, Iacobuzio-Donahue C, Ryu B, 2001, Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7 (12): 3862–3868.PubMedGoogle Scholar
  70. 71.
    Argani P, Rosty C, Reiter RE, 2001, Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarci-noma. Cancer Res 61(11):4320–4324.PubMedGoogle Scholar
  71. 72.
    Hassan R, Remaley AT, Sampson ML, 2006, Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 12 (2):447–453.PubMedGoogle Scholar
  72. 73.
    Hassan R, Bera T, Pastan I. 2004, Mesothelin: a new target for immunotherapy. Clin Cancer Res 10(12 Pt 1):3937–3942.PubMedGoogle Scholar
  73. 74.
    Hassan R, Williams-Gould J, Steinberg SM, 2006, Tumor-directed radiation and the immuno-toxin SS1P in the treatment of mesothelin-expressing tumor xenografts. Clin Cancer Res 12 (16):4983–4988.PubMedGoogle Scholar
  74. 75.
    Wente MN, Jain A, Kono E, 2005, Prostate stem cell antigen is a putative target for immuno-therapy in pancreatic cancer. Pancreas 31 (2): 119–125.PubMedGoogle Scholar
  75. 76.
    Dannull J, Diener PA, Prikler L, 2000, Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 60 (19): 5522–5528.PubMedGoogle Scholar
  76. 77.
    Thomas AM, Santarsiero LM, Lutz ER, 2004, Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 200(3):297–306.PubMedGoogle Scholar
  77. 78.
    Guy CT, Webster MA, Schaller M, 1992, Expression of the neu protooncogene in the mam-mary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A. 89 (22):10578–10582.PubMedGoogle Scholar
  78. 79.
    Greenberg NM, DeMayo F, Finegold MJ, 1995, Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 92(8):3439–3443.PubMedGoogle Scholar
  79. 80.
    Hingorani SR, Petricoin EF, Maitra A, 2003, Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4(6):437–450.PubMedGoogle Scholar
  80. 81.
    Schnare M, Barton GM, Holt AC, 2001, Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2(10):947–950.PubMedGoogle Scholar
  81. 82.
    Sallusto F, Lanzavecchia A. 1994, Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179 (4):1109–1118.PubMedGoogle Scholar
  82. 83.
    Caux C, Massacrier C, Vanbervliet B, 1994, Activation of human dendritic cells through CD40 cross-linking. J Exp Med 180(4):1263–1272.PubMedGoogle Scholar
  83. 84.
    Cella M, Scheidegger D, Palmer-Lehmann K, 1996, Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184(2):747–752.PubMedGoogle Scholar
  84. 85.
    Melero I, Shuford WW, Newby SA, 1997, Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3(6):682–685.PubMedGoogle Scholar
  85. 86.
    Weinberg AD, Rivera MM, Prell R, 2000, Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 164 (4): 2160–2169.PubMedGoogle Scholar
  86. 87.
    Bansal-Pakala P, Jember AG, Croft M. 2001, Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat Med 7(8):907–912.PubMedGoogle Scholar
  87. 88.
    Gjertsen MK, Buanes T, Rosseland AR, 2001, Intradermal ras peptide vaccination with granu-locyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 92(3):441–450.PubMedGoogle Scholar
  88. 89.
    Gjertsen MK, Bakka A, Breivik J, 1995, Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 346(8987):1399–1400.PubMedGoogle Scholar
  89. 90.
    Finn OJ, Jerome KR, Henderson RA, 1995, MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. I mmunol Rev 145:61–89.Google Scholar
  90. 91.
    Ramanathan RK, Lee KM, McKolanis J, 2005, Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 54(3):254–264.PubMedGoogle Scholar
  91. 92.
    Gilliam AD, Topuzov A, Garin AM, 2004, Randomised, double blind, placebo-controlled, multi-centre, group-sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy. Proc Am Soc Clin Oncol 23:A2511.Google Scholar
  92. 93.
    Chen CH, Wang TL, Hung CF, 2000, Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60(4):1035–1042.PubMedGoogle Scholar
  93. 94.
    Hoos A, Levey DL, Lewis JJ. 2004, Autologous heat shock protein-peptide complexes for vaccination against cancer: from bench to bedside. Dev Biol (Basel) 116:109–115; discussion 133-143.Google Scholar
  94. 95.
    Maki RG, Livingston PO, Lewis JJ, 2007, A phase I pilot study of autologous heat shock pro-tein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci 52 (8):1964–1972.PubMedGoogle Scholar
  95. 96.
    Zaremba S, Barzaga E, Zhu M, 1997, I dentification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 57 (20): 4570–4577.PubMedGoogle Scholar
  96. 97.
    Salazar E, Zaremba S, Arlen PM, 2000, Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide. Int J Cancer 85 (6):829–838.PubMedGoogle Scholar
  97. 98.
    Yokokawa J, Palena C, Arlen P, 2005, Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res 11(17):6342–6351.PubMedGoogle Scholar
  98. 99.
    Bhanot U, Heydrich R, Moller P, 2006, Survivin expression in pancreatic intraepithelial neoplasia (PanIN): steady increase along the developmental stages of pancreatic ductal adenocarcinoma. Am J Surg Pathol 30(6):754–759.PubMedGoogle Scholar
  99. 100.
    Wobser M, Keikavoussi P, Kunzmann V, 2006, Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 55(10):1294–1298.PubMedGoogle Scholar
  100. 101.
    Lee MA, Park GS, Lee HJ, 2005, Survivin expression and its clinical significance in pancreatic cancer. BMC Cancer 5:127.PubMedGoogle Scholar
  101. 102. Bernhardt SL, Gjertsen MK, Trachsel S, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 2006.Google Scholar
  102. 103.
    Morse MA, Clay TM, Hobeika AC, 2005, Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 11(8):3017–3024.PubMedGoogle Scholar
  103. 104.
    Dannull J, Su Z, Rizzieri D, 2005, Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115(12):3623–3633.PubMedGoogle Scholar
  104. 105. Bauer C, Dauer M, Saraj S, et al. Immunological and clinical response after vaccination therapy of pancreatic carcinoma patients with autologous, tumor-lysate pulsed dendritic cells: results of a phase ii study. ASCO Annual Meeting 2007.Google Scholar
  105. 106.
    Dranoff G, Jaffee E, Lazenby A, 1993, Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90(8):3539–3543.PubMedGoogle Scholar
  106. 107.
    Cox AL, Skipper J, Chen Y, 1994, Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264(5159):716–719.PubMedGoogle Scholar
  107. 108.
    Kawakami Y, Eliyahu S, Delgado CH, 1994, Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 91(9):3515–3519.PubMedGoogle Scholar
  108. 109.
    Jaffee EM, Hruban RH, Biedrzycki B, 2001, Novel allogeneic granulocyte-macrophage col-ony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. J Clin Oncol 19(1):145–156.PubMedGoogle Scholar
  109. 110. Laheru DA, Yeo C, Biedrzycki B, et al. A safety and efficacy trial of lethally irradiated allo-geneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adju-vant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas. Proc AACR/NCI/EORTC 2005, (C28):204.Google Scholar
  110. 111. Laheru D, Burke J, Biedrzycki B, et al. Allogeneic GM-CSF secreting tumor vaccine (GVAX) alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility and immune activation. Manuscript in preparation.Google Scholar
  111. 112.
    Rossi GR, Mautino MR, Unfer RC, 2005, Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes. Cancer Res 65 (22):10555–10561.PubMedGoogle Scholar
  112. 113.
    Rossi GR, Unfer RC, Seregina T, 2005, Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing alpha(1,3)galactosyl epitopes. Cancer Immunol Immunother 54(10):999–1009.PubMedGoogle Scholar
  113. 114.
    Madan RA, Arlen PM, Gulley JL. 2007, PANVAC-VF: Poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin Biol Ther 7(4):543–554.PubMedGoogle Scholar
  114. 115.
    Brockstedt DG, Giedlin MA, Leong ML, 2004, Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A 101(38):13832–13837.PubMedGoogle Scholar
  115. 116.
    Dietrich G, Spreng S, Favre D, 2003, Live attenuated bacteria as vectors to deliver plasmid DNA vaccines. Curr Opin Mol Ther 5 (1): 10–19.PubMedGoogle Scholar
  116. 117.
    Brockstedt DG, Leong ML, Luckett W, et al. Recombinant Listeria monocytogenes-based immunotherapy targeting mesothelin for the treatment of pancreatic and ovarian cancer. Proc AACR 2005, 46:Abstract 6028.Google Scholar
  117. 118.
    Franzusoff A, Duke RC, King TH, 2005, Yeasts encoding tumour antigens in cancer immu-notherapy. Expert Opin Biol Ther 5(4):565–575.PubMedGoogle Scholar
  118. 119.
    Lu Y, Bellgrau D, Dwyer-Nield LD, 2004, Mutation-selective tumor remission with ras-targeted, whole yeast-based immunotherapy. Cancer Res 64 (15): 5084–5088.PubMedGoogle Scholar
  119. 120.
    Kanda Y, Komatsu Y, Akahane M, 2005, Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation. Transplantation 79 (7):821–827.PubMedGoogle Scholar
  120. 121.
    Haas AR, Sun J, Vachani A, 2006, Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res 12(1):214–222.PubMedGoogle Scholar
  121. 122.
    Pedersen AE, Buus S, Claesson MH. 2006, Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4. Cancer Lett 235(2):229–238.PubMedGoogle Scholar
  122. 123.
    Lenschow DJ, Walunas TL, Bluestone JA. 1996, CD28/B7 system of T cell costimulation. Annu Rev Immunol 14:233–258.PubMedGoogle Scholar
  123. 124.
    Walunas TL, Lenschow DJ, Bakker CY, 1994, CTLA-4 can function as a negative regulator of T cell activation. Immunity 1(5):405–413.PubMedGoogle Scholar
  124. 125.
    Chen L, Ashe S, Brady WA, 1992, Costimulation of antitumor immunity by the B7 counter-receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71(7):1093–1102.PubMedGoogle Scholar
  125. 126.
    Krummel MF, Sullivan TJ, Allison JP. 1996, Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol 8 (4):519–523.PubMedGoogle Scholar
  126. 127.
    Krummel MF, Allison JP. 1995, CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182(2):459–465.PubMedGoogle Scholar
  127. 128.
    Attia P, Phan GQ, Maker AV, 2005, Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23(25):6043–6053.PubMedGoogle Scholar
  128. 129.
    Hirano F, Kaneko K, Tamura H, 2005, Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65 (3): 1089–1096.PubMedGoogle Scholar
  129. 130.
    Strome SE, Dong H, Tamura H, 2003, B7-H1 blockade augments adoptive T-cell immuno-therapy for squamous cell carcinoma. Cancer Res 63 (19): 6501–6505.PubMedGoogle Scholar
  130. 131.
    Dong H, Strome SE, Salomao DR, 2002, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8(8):793–800.PubMedGoogle Scholar
  131. 132.
    Gribben JG, Ryan DP, Boyajian R, 2005, Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 11(12):4430–4436.PubMedGoogle Scholar
  132. 133.
    Schlom J, Arlen PM, Gulley JL. 2007, Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 13(13):3776–3782.PubMedGoogle Scholar
  133. 134.
    Yanagimoto H, Mine T, Yamamoto K, 2007, Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci 98 (4): 605–611.PubMedGoogle Scholar
  134. 135.
    Saji H, Song W, Furumoto K, 2006, Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy. Clin Cancer Res 12 (8):2568–2574.PubMedGoogle Scholar
  135. 136.
    Hiraoka N, Onozato K, Kosuge T, 2006, Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12(18):5423–5434.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Dung Le
    • 1
  • Elizabeth M. Jaffee
    • 1
  • Dan Laheru
    • 1
  1. 1.The Sidney Kimmel Comprehensive Cancer CenterJohn Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations